[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Affiliated Hospital to Academy of Military Medical Sciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":229},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,45,73,98,123,136,163,184,205],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100053499","early-phase-1-car-bcma-70-car-t-cells-for-the-treatment-of-high-risk-plasma-cell-neoplasms-100053499",false,"NCT07416682","CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms","Clinical Study on the Safety and Efficacy of CAR BCMA-CD70 Dual-target CAR-T Therapy for High-risk Plasma Cell Neoplasms","Inclusion Criteria:\n\n1. The subject or their legally acceptable representative has provided written informed consent and is willing and able to comply with all scheduled study visits, study treatment administration, laboratory tests, and other required trial procedures.\n2. Clinically diagnosed with high-risk plasma cell neoplasm, meeting any one of the following molecular\u002Fcytogenetic or clinical criteria:\n\n   1. Deletion of the short arm of chromosome 17 (del(17p)) with clonal proportion ≥ 20%, and\u002For TP53 gene mutation;\n   2. IgH translocation (t(4;14), t(14;16), or t(14;20)) combined with 1q amplification (1q+) and\u002For deletion of the short arm of chromosome 1 (del(1p32));\n   3. Chromosome 1 abnormalities: monoallelic del(1p32) plus 1q+, or biallelic del(1p32);\n   4. β₂-microglobulin ≥ 5.5 mg\u002FL with normal serum creatinine (\\\u003C 1.2 mg\u002FdL).\n3. Age 18 to 75 years (inclusive), male or female.\n4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.\n5. Life expectancy \\> 3 months from the date of signed informed consent.\n6. Hemoglobin (HGB) ≥ 60 g\u002FL (transfusion permitted).\n7. Adequate hepatic, renal, and cardiopulmonary function as defined by:\n\n   1. Serum creatinine ≤ 2 × ULN;\n   2. Left ventricular ejection fraction (LVEF%) ≥ 50%;\n   3. Blood oxygen saturation \\> 90%;\n   4. Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN.\n8. Subject agrees to use highly effective contraception from the date of informed consent until 1 year after CAR-T cell infusion.\n\nExclusion Criteria:\n\n1. Severe cardiac insufficiency with left ventricular ejection fraction (LVEF%) \\\u003C 50%.\n2. History of severe chronic lung disease associated with impaired pulmonary function.\n3. Concurrent active or progressive malignant tumors other than the target plasma cell neoplasm.\n4. Concurrent severe infection that cannot be effectively controlled with standard therapy.\n5. Concurrent severe autoimmune disease or congenital immunodeficiency disorders.\n6. Active viral hepatitis, defined as hepatitis B virus DNA (HBV-DNA) or hepatitis C virus RNA (HCV-RNA) levels above the lower limit of detection (LLOD).\n7. Human immunodeficiency virus (HIV) infection, known acquired immunodeficiency syndrome (AIDS), or syphilis infection.\n8. History of severe allergic reactions to biological products, including antibiotics.\n9. Recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with persistent acute graft-versus-host disease (aGVHD) that does not resolve within 1 month after discontinuing immunosuppressive therapy.\n10. Presence of other severe physical or psychiatric illnesses, or significant laboratory abnormalities, that may increase the risks of study participation, interfere with study outcomes, or render the subject otherwise unsuitable for enrollment as determined by the investigator.\n11. Female subjects of childbearing potential who are pregnant or breastfeeding.","ALL","18 Years","75 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","This is a single arm study to evaluate the safety and efficacy of CAR BCMA-CD70 CAR-T cell therapy for high-risk plasma cell neoplasms.",[27],"High-risk Plasma Cell Neoplasms",[27,29,30,31],"BCMA","CD70","CAR-T","RECRUITING","2026-07-10",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2026-04-14",{"date":40,"type":21},"2028-01-30",{"name":42,"class":43},"Affiliated Hospital to Academy of Military Medical Sciences","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":44},"100640767","a-novel-two-tooth-clip-for-esd-and-eftr-of-gist-100640767","NCT07581977","A Novel Two-Tooth Clip for ESD and EFTR of GIST","Efficacy and Safety of a Novel Two-Tooth Clip-Assisted ESD and EFTR of GIST: A Single-Center, Prospective, Open-Label, Randomized Controlled Study","Inclusion Criteria:\n\n* Age ≥ 18 and ≤ 85 years.\n* Patients diagnosed with gastric gastrointestinal lesions clinically indicated for ESD or EFTR.\n* Lesion size between 2 cm and 5 cm in diameter.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Lesions with clear evidence of deep submucosal invasion or distant metastasis precluding curative endoscopic resection.\n* Severe coagulation dysfunction (international normalized ratio \\>2.0, platelet count \\\u003C50,000\u002FµL) or ongoing use of dual antiplatelet therapy\u002Fanticoagulants that cannot be appropriately bridged or discontinued per guidelines.\n* Severe organ failure (cardiac, renal, hepatic, or respiratory) rendering the patient unsuitable for prolonged sedation or general anesthesia.\n* Pregnancy or lactation.\n* Prior surgical or endoscopic intervention at the target lesion site that results in significant fibrosis.","85 Years",{"count":54,"type":21},60,[56],"NA","This study is designed to evaluate the efficacy and safety of a novel two-tooth endoscopic clip, utilized in a \"clip with line\" traction configuration, during endoscopic resection procedures (ESD and EFTR) of GIST. The novel clip's dual-tooth design is intended to provide a more secure anchor on the lesion, enabling effective counter-traction when combined with a line. The primary aim is to determine if this method improves submucosal dissection efficiency compared to conventional ESD. A secondary aim is to evaluate the performance of the same clip system for full-thickness or mucosal defect closure.",[59],"GIST - Gastrointestinal Stromal Tumor",[61,62,63,64],"GIST","ESD","EFTR","two-tooth clips","2026-05-20",{"date":67,"type":36},"2026-05-22",{"date":69,"type":36},"2026-04-24",{"date":71,"type":21},"2027-07-01",{"name":42,"class":43},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100634972","early-phase-1-nanobody-based-cd19cd20-tandem-dual-car-t-cell-therapy-of-relapsedrefractory-b-cell-lymphoma-100634972","NCT07546630","Nanobody-Based CD19\u002FCD20 Tandem Dual CAR-T-cell Therapy of Relapsed\u002FRefractory B-Cell Lymphoma","Clinical Study on the Safety and Efficacy of Nanobody-Based CD19\u002FCD20 Tandem Dual CAR-T-cell Therapy for Relapsed\u002FRefractory B-Cell Lymphoma","Inclusion Criteria:\n\n1. The subject has voluntarily signed the informed consent form with full consent, and is willing and able to comply with the scheduled visits, study treatments, laboratory tests, and other trial procedures\n2. Patients with relapsed\u002Frefractory B-cell lymphoma confirmed by cytology or histology according to the WHO 2022 Classification:\n\n   * Lymphoma cells confirmed to express CD19 and\u002For CD20 antigen by immunophenotyping or histopathological immunohistochemistry\n   * B-cell lymphomas include: aggressive B-cell lymphomas (LBCL, BL, MCL) and indolent B-cell lymphomas (CLL\u002FSLL, FL, MZL, LPL, HCL)\n   * Relapsed\u002Frefractory B-cell lymphoma: For patients with aggressive lymphoma, disease stable for ≤12 months or disease progression after achieving best response following at least first- and second-line pharmacotherapy; or disease progression or relapse within ≤12 months after autologous stem cell transplantation. For patients with indolent lymphoma, disease progression, relapse or transformation following at least three lines of prior therapy\n3. Aged 18-75 years (inclusive), male or female\n4. Subjects with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2\n5. Estimated overall survival of more than 3 months from the date of signing the informed consent form\n6. Hemoglobin (HGB) ≥ 70 g\u002FL (transfusion permitted)\n7. Adequate hepatic, renal and cardiopulmonary function meeting the following criteria:\n\n   * Creatinine ≤ 1.5 × ULN;\n   * Left ventricular ejection fraction (LVEF) ≥ 50%;\n   * Blood oxygen saturation \\> 90%;\n   * Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN\n8. The subject agrees to use contraceptive measures from the date of signing the informed consent form until 1 year after CAR-T cell infusion\n\nExclusion Criteria:\n\n* Severe cardiac insufficiency with left ventricular ejection fraction \\\u003C 50%\n* History of severe pulmonary function-impairing diseases\n* Concomitant other advanced malignant neoplasms\n* Concomitant severe infection that cannot be effectively controlled\n* Concomitant severe autoimmune diseases or congenital immunodeficiency disorders\n* Active hepatitis (hepatitis B virus deoxyribonucleic acid \\[HBV-DNA\\] or hepatitis C virus ribonucleic acid \\[HCV-RNA\\] test result above the lower limit of detection)\n* Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection\n* History of severe allergy to biological products (including antibiotics)\n* Patients with allogeneic hematopoietic stem cell transplantation who still have acute graft-versus-host disease (GVHD) after one month of discontinuation of immunosuppressive agents",{"count":20,"type":21},[24],"This is a single arm study to evaluate the safety and efficacy of Nanobody-Based CD19\u002FCD20 Tandem Dual CAR-T-cell therapy for Relapsed\u002FRefractory B-Cell Lymphoma",[84],"Relapsed\u002FRefractory B-Cell Lymphoma",[84,86,87,88,31],"Nanobody","CD19","CD20","NOT_YET_RECRUITING","2026-04-23",{"date":92,"type":36},"2026-04-29",{"date":94,"type":21},"2026-04-30",{"date":96,"type":21},"2029-05-01",{"name":42,"class":43},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":44},"100591900","early-phase-1-car19bcma-car-t-cells-for-the-treatment-of-rr-plasma-cell-neoplasms-and-lymphomasleukemias-with-plasmacytic-differentiation-100591900","NCT06986434","CAR19BCMA CAR-T Cells for the Treatment of R\u002FR Plasma Cell Neoplasms and Lymphomas\u002FLeukemias With Plasmacytic Differentiation","A Clinical Study on the Safety and Efficacy of CAR19-BCMA Dual-target CAR-T Cell Therapy for Relapsed\u002FRefractory Plasma Cell Neoplasms and Lymphomas\u002FLeukemias With Plasmacytic Differentiation","Inclusion Criteria:\n\n1. Relapsed\u002Frefractory CD19BCMA positive plasma cell neoplasms and lymphomas\u002Fleukemias with plasmacytic differentiation must be assured and meet all of the following conditions:\n\n   * Confirmation for either BCMA or CD19 positivity using immunohistochemistry or flow cytometry\n   * Patients with multiple myeloma, plasma cell carcinoma, plasma cell leukemia and lymphomas\u002Fleukemias with plasmacytic differentiation who have received at least three 3 lines treatment (including anti-CD38 monoclonal antibodies, protease inhibitors, immunosuppressants, etc.) but have failed or experienced relapse\n   * Patients with system light chain amyloidosis who have received at least 2 lines treatments in the past \\[anti-CD38 monoclonal antibody, proteasome inhibitor (PI), or immunomodulatory drug (IMiD)\\], but have failed or experienced relapse\n2. Age 18-80 years, no gender restrictions\n3. ECOG score ≤ 2 points\n4. Expected survival period is not less than 3 months\n5. HGB≥60g\u002FL\n6. Liver function and cardiopulmonary function meet the following requirements:\n\n   * left ventricular ejection fraction≥50%\n   * Oxygen saturation \\>90%\n   * Total bilirubin ≤1.5×ULN, ALT and AST≤2.5×ULN\n7. Participants agreed to use contraception from the time of informed consent until 1 year after CAR-T cell infusion\n\nExclusion Criteria:\n\n* Severe heart failure with left ventricular ejection fraction \\\u003C50%\n* A history of severe lung function impairment\n* Combined with other advanced malignant tumors\n* Complicated with severe infection that could not be effectively controlled\n* Severe autoimmune disease or congenital immune deficiency\n* Active hepatitis (hepatitis B virus DNA \\[HBV-DNA\\] or hepatitis C virus RNA \\[HCV-RNA\\] test results above the lower limit of detection)\n* Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection\n* History of severe allergy to biological products (including antibiotics)\n* Patients with other serious physical or mental illnesses or laboratory abnormalities that could increase the risk of participating in the study or interfere with the results of the study, and those who were deemed by the investigator to be unsuitable for participation in the study\n* Female patients (those with fertility) are in pregnancy or lactation",{"count":20,"type":21},[24],"This is a single arm study to evaluate the safety and efficacy of CAR19BCMA CAR-T cells in the treatment of relapsed\u002Frefractory CD19\u002FBCMA positive plasma cell neoplasms and lymphomas\u002Fleukemias with plasmacytic differentiation.",[109,110],"Relapsed or Refractory Plasma Cell Neoplasms","Lymphomas\u002FLeukemias With Plasmacytic Differentiation",[31,112,113,114],"plasma cell neoplasms","CD19\u002FBCMA","lymphomas\u002Fleukemias with plasmacytic differentiation","2026-04-07",{"date":117,"type":36},"2026-04-08",{"date":119,"type":21},"2026-04-02",{"date":121,"type":21},"2028-08-25",{"name":42,"class":43},{"id":124,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":25,"conditions":127,"keywords":128,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":135,"locationsCount":44},"100624980",{"count":20,"type":21},[24],[27],[27,29,30,31],"2026-02-23",{"date":131,"type":36},"2026-02-25",{"date":133,"type":21},"2026-01-31",{"date":40,"type":21},{"name":42,"class":43},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":143,"maxAge":18,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":44},"100580225","phase-1-car2219-car-t-cells-for-the-treatment-of-rr-b-cell-leukemia-and-lymphoma-100580225","NCT06834529","CAR2219 CAR-T Cells for the Treatment of R\u002FR B Cell Leukemia and Lymphoma","Safety and Efficacy of CAR2219 CAR-T Cells in Treatment of Relapsed\u002Frefractory CD19\u002FCD22 Positive B Cell Leukemia and Lymphoma","Inclusion Criteria:\n\n1. Signed written informed consent;\n2. Relapsed\u002Frefractory CD19\u002FCD22 positive B cell Leukemia or Lymphoma must be assured and meet one of the following conditions: (1) Confirmation for either CD19 or CD22 positivity using immunohistochemistry or flow cytometry; (2) B-cell tumors include the following three categories: ① B-cell acute lymphoblastic leukemia (B-ALL); Indolent B-cell lymphoma (CLL, FL, MZL, LPL, HCL); Aggressive B-cell lymphoma (DLBCL, BL, MCL) (3) Refractory\u002Frecurrent B-ALL (include one of the following situations) : ① relapse within 12 months after the first remission; ② The first refractory patients who did not achieve complete remission after 2 cycles of standard chemotherapy regimen; ③ Failure to achieve complete remission or relapse after first-line or multi-line salvage chemotherapy; ④ Recurrence after hematopoietic stem cell transplantation. (4) Refractory\u002Frecurrent B-cell lymphoma (meeting the requirements of 1 of the first 4 below plus 5) : ① After 4 courses of chemotherapy prescribed by the standard protocol, the tumor has shrunk by less than 50% or the disease progression(PD); ② CR reached after standard chemotherapy, but relapse occurred within 12 months; ③ Two or more recurrence after CR; ④ Recurrence after hematopoietic stem cell transplantation; ⑤Patients must have received rituximab or another anti-CD20 monoclonal antibody (unless Investigator determines that tumor is CD20-negative) and an anthracycline-containing chemotherapy regimen.\n3. All genders, ages: 14 to 75 years\n4. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2.\n5. Life expectancy ≥3 months;\n6. HGB≥70g\u002FL\n7. Liver,kidney function and cardiopulmonary function meet the following requirements: (1) creatinine ≤1.5×ULN; (2) left ventricular ejection fraction≥50%; (3) Oxygen saturation \\>90%; (4) Total bilirubin ≤1.5×ULN, ALT and AST≤2.5×ULN;\n8. Participants agreed to use contraception from the time of informed consent until 1 year after CAR-T cell infusion.\"\n\nExclusion Criteria:\n\n1. Severe heart failure with left ventricular ejection fraction \\\u003C50%;\n2. A history of severe lung function impairment;\n3. Combined with other advanced malignant tumors;\n4. Complicated with severe infection that could not be effectively controlled;\n5. Severe autoimmune disease or congenital immune deficiency;\n6. Active hepatitis (hepatitis B virus DNA \\[HBV-DNA\\] or hepatitis C virus RNA \\[HCV-RNA\\] test results above the lower limit of detection);\n7. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection;\n8. History of severe allergy to biological products (including antibiotics);\n9. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients with acute graft-versus-host reaction (GVHD) one month after immunosuppressant withdrawal;\n10. Patients with other serious physical or mental illnesses or laboratory abnormalities that could increase the risk of participating in the study or interfere with the results of the study, and those who were deemed by the investigator to be unsuitable for participation in the study.","14 Years",{"count":20,"type":21},[146,147],"PHASE1","PHASE2","This is a single arm study to evaluate the safety and efficacy of CAR2219 CAR-T cells in the treatment of relapsed\u002Frefractory CD19\u002FCD22 positive B cell Leukemia and Lymphoma.",[150],"Relapsed or Refractory B Cell Leukemia and Lymphoma",[31,152,153,154],"B cell Leukemia","B cell Lymphoma","CD19\u002FCD22","2025-02-13",{"date":157,"type":36},"2025-02-19",{"date":159,"type":36},"2025-01-20",{"date":161,"type":21},"2027-01-31",{"name":42,"class":43},{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":44},"100201442","phase-1-dcs-vaccine-combined-with-cytokine-induced-killer-cells-in-patients-with-aml-100201442","NCT01898663","DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML","Safety and Therapeutic Efficacy of DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML: a Phase Ⅰ\u002FⅡ Study","Inclusion Criteria:\n\n* Consistent with the diagnosis of AML\n* Age≥18 years at time of consent\n* KPS(Karnofsky Performance Scale) ≥70\n* Patient's written informed consent\n* No steroid therapy within 4 weeks of first DC vaccination\n* Stable disease, complete response and partial response(WHO, RECIST)\n* Predicted survival≥3 months\n\nExclusion Criteria:\n\n* Serious dysfunction of vital organs(heart, liver or kidney)\n* Received organ transplantation\n* Patients with other malignancies or brain metastases\n* History of autoimmune diseases\n* Pregnant and breast-feeding patient\n* Active or chronic infectious diseases\n* History of allergy or hypersensitivity to study product excipients\n* Currently participating in another clinical trial\n* Received chemotherapy, radiotherapy, immune inhibitor (such as corticosteroid) or other immunotherapy (such as vaccine) during prior 4 weeks\n* Unfit for participating in this clinical trial in investigators' opinions",{"count":171,"type":21},30,[146,147],"The aim of this Phase Ⅰ\u002FⅡ study is to evaluate the safety and efficacy of dendritic cells (DCs) vaccine combined with cytokine-induced killer (CIK) cells in patients with AML. Experimental recombinant adenovirus-transfected DCs, which engineered to express MUC1 and Survivin are used for DCs-based immunotherapy. Based on the results of our previously performed preclinical study with DCs vaccine combined with CIK cells, the investigators plan to perform the clinical trial.",[175],"High-risk Soft Tissue Sarcoma","2024-06-28",{"date":178,"type":36},"2024-07-01",{"date":180,"type":4},"2013-06",{"date":182,"type":21},"2024-12-30",{"name":42,"class":43},{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":44},"100439323","clinical-study-of-dc-aml-cells-in-the-treatment-of-acute-myeloid-leukemia-100439323","NCT05000801","Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia","Safety and Feasibility Study of Dendritic Cell (DC) Vaccination Expressing WT1\u002FhTERT\u002FSurvivin in AML Patients With Minimal Residual Disease (MRD)","Inclusion Criteria:\n\n* Diagnosis of acute myeloid leukemia (AML) according to the 2008 criteria of the World Health Organization (WHO).\n* Patients completed induction and consolidation chemotherapy and have achieved complete remission (CR) by bone marrow biopsy criteria but with persistent MRD (defined by upregulated WT1 level and less than 5% of blast cells in bone marrow biopsy) and are not eligible for stem cell transplant\n* Patients have MRD molecular relapse (defined by upregulated WT1 level and less than 5% of blast cells in bone marrow biopsy) after achieved CR following induction and consolidation chemotherapy.\n* Patients with molecular relapse (define by upregulated WT1 level and less than 5% of blast cells in bone marrow biopsy) after allogeneic stem cell transplant\n* Leukemic cells express at least one of the following antigens: WT1, hTERT or survivin detected by qRT-PCR and\u002For flow cytometry or immunohistochemistry\n* Karnofsky PS ≥60% or ECOG PS≤2.\n* Patients must have organ and marrow function as defined below:\n\n  * leukocytes \\>=3,000\u002FmcL\n  * absolute neutrophil count \\>=1,500\u002FmcL\n  * platelets \\>=100,000\u002FmcL\n  * hemoglobin \\>=9.0 g\u002FdL\n  * total bilirubin within normal institutional limits except in patients with Gilberts Syndrome who must have a total bilirubin \\\u003C 3.0 mg\u002FdL\n  * AST(SGOT)\u002FALT(SGPT) Serum ALT\u002FAST \\\u003C 2.5X ULN\n  * creatinine clearance Calculated creatinine clearance (CrCl) \\>=50 mL\u002Fmin\u002F1.73 m\\^2 for patients with creatinine levels above institutional normal (by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation)\n  * Adequate cardiac function: LVEF ≥50% by MUGA\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participation in any other interventional clinical trial during the study period.\n* History or concomitant presence of any other malignancy, except for any other effectively treated malignancy that has been in remission for \\>5 years or that is highly likely to be cured at the time of enrollment.\n* Patients with a second invasive malignancy requiring treatment within the last 2 years are not eligible.\n* Patients with any form of systemic immunodeficiency, including AIDS or primary immunodeficiency such as Severe Combined Immunodeficiency Disease, are ineligible. The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the treatment.\n* Active hepatitis B, C infection\n* Patients on immunosuppressive drugs including corticosteroids.\n* Patients with autoimmune diseases such as Crohn s disease, ulcerative colitis, rheumatoid arthritis, autoimmune hepatitis, autoimmune pancreatitis, or systemic lupus erythematosus.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations at the time of treatment that would limit compliance with study requirements.\n* Allergic to human albumin or IL-2. History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in study.\n* Pregnant or breast-feeding.","70 Years",{"count":20,"type":21},[56],"The primary aim of this innovative immunotherapy using WT1\u002FhTERT\u002FSurvivin-loaded DCs is to determine whether this novel DC vaccination is safe and can significantly prevent clinical relapse and increase survival of acute myeloid leukemia (AML) patients by eradicating minimal residual disease, while maintaining its safety profile in this phase I trial.",[196],"Acute Myeloid Leukemia","2021-08-16",{"date":199,"type":36},"2021-08-20",{"date":201,"type":36},"2021-07-01",{"date":203,"type":21},"2026-07-01",{"name":42,"class":43},{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":16,"minAge":213,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":22,"phases":216,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":227,"leadSponsor":228,"locationsCount":44},"100439257","phase-1-hypomemylating-agents-combination-with-edc-therapy-for-elderly-patients-with-myelodysplastic-syndrome-100439257","NCT04999943","Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome","A Randomized, Open-label, Clinical Trial to Compare the Safety and Efficacy of Hypomemylating Agents Monotherapy and Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome","eDC-MDS","Inclusion Criteria:\n\n1. elderly MDS patients;\n2. aged more than 60 years old, general condition, ECOG score less than 1;\n3. normal function of heart, liver and kidney, serum bilirubin ≤ 35 umol \u002F L; serum creatinine ≤ 150 umol \u002F L;\n4. patients are unsuitable or unwilling to receive hematopoietic stem cell transplantation;\n5. subjects sign informed consent.\n\nExclusion criteria:\n\n1. serious infection was not controlled before treatment;\n2. contraindications for the use of dexitabine and azacytidine;\n3. other cases that did not meet the admission criteria.","60 Years",{"count":215,"type":21},40,[146],"The purpose of this study is to optimize the traditional treatment scheme and explore the cure scheme for the elderly by combining the existing mature treatment technology. The primary aim of this innovative immunotherapy using WT1\u002FhTERT\u002FSurvivin-loaded DCs is to determine whether this novel DC vaccination is safe and can significantly prevent clinical relapse and increase survival of MDS patients.",[219,220,221,222],"Myelodysplastic Syndromes","Dendritic Cell","Hypomethylating Agents","Immunotherapy","2021-08-10",{"date":225,"type":36},"2021-08-11",{"date":201,"type":36},{"date":203,"type":21},{"name":42,"class":43},""]